BYAH is trading 8.5% down at $1.07 following renewed concerns regarding share dilution and financing pressure.
- Investors are focused on the impact of a recent $2 million registered direct offering, which has triggered fears of potential share value dilution.
- The selling pressure is currently outweighing market optimism surrounding Park Ha Biological Technology’s newly announced strategic cooperation with Amazon North America for personal care products.